199 Biotechnologies
About 199 Biotechnologies
199 Biotechnologies develops first-in-class therapeutics that utilize epigenetic reprogramming to target cancer cells, particularly focusing on brain cancer, by reversing malignant cellular programming and inducing natural senescent apoptosis. This approach addresses the limitations of traditional cancer treatments, which often lead to resistance and recurrence, by restoring normal cellular function while minimizing damage to healthy tissue.
```xml <problem> Traditional cancer treatments often focus on cell death, leading to resistance, recurrence, and damage to healthy tissue, particularly in difficult-to-treat cancers like those of the brain. Age-related epigenetic alterations drive tumor growth, invasion, and therapy resistance, but few treatments effectively target these fundamental changes to restore normal cellular function. </problem> <solution> 199 Biotechnologies is developing first-in-class therapeutics that utilize epigenetic reprogramming to target cancer cells. Their approach aims to reverse malignant cellular programming and induce natural senescent apoptosis, addressing the limitations of traditional treatments. The company's technology modulates specific epigenetic pathways to reverse malignant cellular programming, induce natural senescent anaphylaxis, target therapy-resistant cancer cells, prevent metastasis, and control tumor growth and invasion. 199 Biotechnologies is developing mRNA and cell therapy platforms to deliver reprogramming factors to cancer cells, with a focus on optimizing delivery techniques for maximum efficacy and safety, particularly in brain cancer applications. </solution> <features> - Cancer-specific reprogramming via epigenetic mechanisms - mRNA platform utilizing novel delivery vehicles based on phase separation technology - Cell therapy platform leveraging advanced engineering techniques for precise targeting - Organ-on-a-chip technology to simulate human organ systems in vitro for studying the effects of epigenetic rejuvenation - Targets multiple aspects of cancer biology, including growth, proliferation, invasion, migration, metastatic potential, and cancer stem cells </features> <target_audience> The primary target audience includes cancer patients, particularly those with brain cancer, and healthcare providers seeking more effective and targeted cancer therapies. </target_audience> <revenue_model> The company has raised $6.5M in seed funding to support the development of its epigenetic anti-aging therapy. </revenue_model> ```
What does 199 Biotechnologies do?
199 Biotechnologies develops first-in-class therapeutics that utilize epigenetic reprogramming to target cancer cells, particularly focusing on brain cancer, by reversing malignant cellular programming and inducing natural senescent apoptosis. This approach addresses the limitations of traditional cancer treatments, which often lead to resistance and recurrence, by restoring normal cellular function while minimizing damage to healthy tissue.
Where is 199 Biotechnologies located?
199 Biotechnologies is based in Andé, Germany.
When was 199 Biotechnologies founded?
199 Biotechnologies was founded in 2023.
How much funding has 199 Biotechnologies raised?
199 Biotechnologies has raised 6310000.
- Location
- Andé, Germany
- Founded
- 2023
- Funding
- 6310000
- Employees
- 9 employees